Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Perrigo Deal Makes Extraction-Resistant PSE A Two-Player Competition

Executive Summary

Via Highland Pharmaceuticals agreement, Perrigo snaps up the only tamper-resistant pseudoephedrine formulation still available for licensing. It now goes up against Bayer – but will beat the pharma giant to market.

Advertisement

Related Content

Indiana Ups State Power To Limit Pseudoephedrine Product Sales
Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor
Tamper-Resistant PSE Takes Big Pharma Stage: Bayer Licenses Acura’s Formulation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register